This exciting development is set to enhance nutritional care and support for patients across the country
Chanson International Holding, a provider of bakery, seasonal, and beverage products through its chain stores in China and the United States, announced that its self-developed “Songkang Meal” series of nasogastric nutrition formulas has received official registration approval as a Food for Special Medical Purpose (FSMP) in China. The product has been adopted for use in several hospitals in Xinjiang. As the Company’s first FSMP product, “Songkang Meal” represents Chanson’s expansion into the medical nutrition and FSMP market, presenting an opportunity for new revenue streams.
“Songkang Meal” is designed to address the market need for FSMP products in Northwest China with its nutritional formulation and localised features. Specifically developed for patients with chronic conditions such as diabetes and kidney disease, the “Songkang Meal” series utilises a low-glycemic index carbohydrate and plant-based protein blend to balance nutrient density and gastrointestinal tolerance. Its formulation also incorporates ingredients native to Xinjiang, including sea buckthorn and chickpeas. At one hospital in Xinjiang, 127 patients have reportedly used the product, increasing nutritional compliance rates. In its first month on the market, “Songkang Meal” was used by over 1,000 patients, achieving satisfactory results. These initial results indicate positive reception in the region.
Chanson’s entry into the FSMP field builds on its experience in food innovation. Drawing from years of experience in bakery production, the Company has applied relevant technologies such as freeze-drying and precision temperature control to the development of stable and high-quality nutrition formulas. By sourcing ingredients locally and centralising production in Xinjiang, Chanson aims to achieve cost efficiency and raw material traceability. Additionally, the Company’s existing retail network in Xinjiang supports a logistics system capable of delivering FSMP products to hospital partners within 48 hours, addressing a major challenge of cold-chain distribution in the market.
